CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $850,400 | +4713.8% | 47,192 | +4190.2% | 0.01% | – |
| Q1 2023 | $17,666 | -53.5% | 1,100 | -42.9% | 0.00% | – |
| Q3 2022 | $38,000 | -75.9% | 1,925 | -77.3% | 0.00% | -100.0% |
| Q2 2022 | $158,000 | +45.0% | 8,478 | +70.4% | 0.00% | 0.0% |
| Q1 2022 | $109,000 | +137.0% | 4,975 | +205.8% | 0.00% | – |
| Q4 2021 | $46,000 | -89.6% | 1,627 | -92.2% | 0.00% | -100.0% |
| Q3 2021 | $441,000 | +90.9% | 20,938 | +70.5% | 0.01% | +100.0% |
| Q2 2021 | $231,000 | – | 12,281 | +72141.2% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 17 | -98.5% | 0.00% | – |
| Q4 2020 | $16,000 | -38.5% | 1,168 | -21.2% | 0.00% | – |
| Q2 2020 | $26,000 | -78.0% | 1,483 | -68.4% | 0.00% | -100.0% |
| Q4 2019 | $118,000 | +337.0% | 4,700 | +164.3% | 0.00% | +100.0% |
| Q3 2019 | $27,000 | – | 1,778 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |